Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

164.34 +1.17 (+0.72%)

Delayed Quote Updated: 3:29 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

10 Analysts Have This To Say About Glaukos ↗

July 10, 2024

Via Benzinga

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

July 10, 2024

Via Benzinga

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

July 10, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

June 14, 2024

From Glaukos Corporation

Via Business Wire

Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings) ↗

May 22, 2024

Via Benzinga

Analyst Ratings For Glaukos ↗

April 08, 2024

Via Benzinga

5 Analysts Have This To Say About Glaukos ↗

March 22, 2024

Via Benzinga

Glaukos Announces Participation in Upcoming Investor Conferences

May 28, 2024

From Glaukos Corporation

Via Business Wire

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst ↗

May 02, 2024

Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.

Via Benzinga

Topics Earnings

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday ↗

May 02, 2024

Via Benzinga

Glaukos: Q4 Earnings Insights ↗

February 21, 2024

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

Analyst Ratings For Glaukos ↗

February 16, 2024

Via Benzinga

Unveiling 7 Analyst Insights On Glaukos ↗

December 21, 2023

Via Benzinga

GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Glaukos Announces First Quarter 2024 Financial Results

May 01, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces the Release of its 2023 Sustainability Report

April 16, 2024

From Glaukos Corporation

Via Business Wire

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

April 10, 2024

From Glaukos Corporation

Via Business Wire

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday ↗

April 03, 2024

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

Via Benzinga

Topics Stocks

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

April 03, 2024

From Glaukos Corporation

Via Business Wire

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

April 01, 2024

From Glaukos Corporation

Via Business Wire

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 22, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024

From Glaukos Corporation

Via Business Wire

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

January 31, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

January 09, 2024

From Glaukos Corporation

Via Business Wire

Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst ↗

December 21, 2023

Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.

Via Benzinga

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 21, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 20, 2023

From Glaukos Corporation

Via Business Wire

iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst ↗

December 15, 2023

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog...

Via Benzinga

Dow Extends Rally As Treasury Yields Tank ↗

December 14, 2023

The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision.

Via Talk Markets

Topics Economy Stocks

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.